 Shares of Vir Biotechnology Inc. VIR, -1.60 were up 1.0 in trading on Thursday after the company and GlaxoSmithKline GSK, -0.01 formally asked the Food and Drug Administration to update the authorization for their COVID-19 treatment to include intramuscular administration. GSKs stock was up 0.1 after the news was announced. 